Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sattler

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
Scientific Reports|April 16, 2016
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesotheliomaFrances E Lennon, Gianguido C Cianci, Rajani Kanteti, et al.
Cancer Research|June 11, 2009
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myelomaJing Zhang, Martin Sattler, Giovanni Tonon, et al.
Cancer Cell|July 19, 2002
Critical role for Gab2 in transformation by BCR/ABLMartin Sattler, M Golam Mohi, Yuri B Pride, et al.
Leukemia|August 29, 2019
Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.
Journal of Cellular and Molecular Medicine|January 17, 2020
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutationsEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.
Leukemia|March 8, 2020
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.
Blood|April 3, 2015
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approachAtsushi Nonami, Martin Sattler, Ellen Weisberg, et al.
Cancers|October 14, 2022
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint InhibitorsDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
NPJ Precision Oncology|June 19, 2024
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcomeDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
British Journal of Haematology|July 17, 2019
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignanciesEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
Scientific Reports|April 16, 2016
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesotheliomaFrances E Lennon, Gianguido C Cianci, Rajani Kanteti, et al.
Cancer Research|June 11, 2009
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myelomaJing Zhang, Martin Sattler, Giovanni Tonon, et al.
Cancer Cell|July 19, 2002
Critical role for Gab2 in transformation by BCR/ABLMartin Sattler, M Golam Mohi, Yuri B Pride, et al.
Leukemia|August 29, 2019
Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.
Journal of Cellular and Molecular Medicine|January 17, 2020
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutationsEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.
Leukemia|March 8, 2020
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.
Blood|April 3, 2015
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approachAtsushi Nonami, Martin Sattler, Ellen Weisberg, et al.
Cancers|October 14, 2022
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint InhibitorsDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
NPJ Precision Oncology|June 19, 2024
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcomeDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
British Journal of Haematology|July 17, 2019
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignanciesEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.
Pageof 13